Andrew Lam has over two decades of biopharma-focused experience spanning operating roles in the industry and corporate finance. He is currently the Managing Director and Head of Biotech Private Equity at Ally Bridge Group, a New York-based, global healthcare investment management firm focused on high-impact life science innovation, where he leads therapeutic investments in private biotech companies.

Before joining Ally Bridge Group in 2021, Andrew was Senior Director of Business Development at Intercept Pharmaceuticals. Previously, Andrew was Vice President, Healthcare Investment Banking at Jefferies, Equity Research Associate at BMO Capital and at Canaccord Genuity. Andrew began his career in Medical Affairs at several biotechnology companies, including Shire and Celgene.

Andrew founded Life Sciences Sherpas in 2021, a volunteer organized collective that aims to foster life sciences collaboration by improving stakeholder connectivity.

Andrew holds a PharmD from Long Island University and received an MBA from Drexel University.